Literature DB >> 1603343

The Rochester Diabetic Neuropathy Study: reassessment of tests and criteria for diagnosis and staged severity.

P J Dyck1, J L Karnes, P C O'Brien, W J Litchy, P A Low, L J Melton.   

Abstract

We evaluated the initial assessments of the 380 diabetic patients with and without polyneuropathy in the Rochester Diabetic Neuropathy Study for (1) associations among neuropathy test results, (2) usefulness of different tests for diagnosing and staging polyneuropathy, (3) appropriateness of different minimal criteria for the diagnosis of polyneuropathy, and (4) significant differences in test results with increasing stage of polyneuropathy. Nerve conduction ([NC]; abnormality in two or more nerves) and quantitative autonomic examination ([QAE]; decreased heart-beat response to deep breathing [DB] or the Valsalva maneuver [VAL]) were the most sensitive and objective and were especially suitable for detection of subclinical neuropathy. We propose the following minimal criteria for the diagnosis of diabetic polyneuropathy: greater than or equal to 2 abnormal evaluations (from among neuropathic symptoms, neuropathic deficits, NC, quantitative sensory examination [QSE], and QAE) with one of the two being abnormality of NC or QAE (DB or VAL). Neuropathy Symptom Score, Neuropathy Disability Score, QSE (vibratory or cooling detection threshold), and summated compound muscle action potential of ulnar, peroneal, and tibial nerves were best for judging severity. Inability to walk on heels provided a discrete separation of diabetic patients into those with mild and those with more severe neuropathy--a separation helpful in staging.

Entities:  

Mesh:

Year:  1992        PMID: 1603343     DOI: 10.1212/wnl.42.6.1164

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  39 in total

1.  Symptomatic focal mononeuropathies in diabetic patients: increased or not?

Authors:  Elefterios Stamboulis; Demetris Vassilopoulos; Nikolaos Kalfakis
Journal:  J Neurol       Date:  2005-02-23       Impact factor: 4.849

2.  Reliability of quantitative sudomotor axon reflex testing and quantitative sensory testing in neuropathy of impaired glucose regulation.

Authors:  Amanda Peltier; A Gordon Smith; James W Russell; Kiran Sheikh; Billie Bixby; James Howard; Jonathan Goldstein; Yanna Song; Lily Wang; Eva L Feldman; J Robinson Singleton
Journal:  Muscle Nerve       Date:  2009-04       Impact factor: 3.217

Review 3.  [Diabetic neuropathy].

Authors:  Monika Lechleitner; Heidemarie Abrahamian; Claudia Francesconi; Markus Kofler
Journal:  Wien Klin Wochenschr       Date:  2016-04       Impact factor: 1.704

Review 4.  Diabetes mellitus and the nervous system.

Authors:  P J Watkins; P K Thomas
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-11       Impact factor: 10.154

Review 5.  Entrapment neuropathies in diabetes mellitus.

Authors:  Eugenia Rota; Nicola Morelli
Journal:  World J Diabetes       Date:  2016-09-15

Review 6.  Gastrointestinal disturbances in diabetes.

Authors:  Manju Chandran; Neelima V Chu; Steven V Edelman
Journal:  Curr Diab Rep       Date:  2003-02       Impact factor: 4.810

Review 7.  Neurologic complications of diabetes.

Authors:  Gerald A Charnogursky; Nicholas V Emanuele; Mary Ann Emanuele
Journal:  Curr Neurol Neurosci Rep       Date:  2014-07       Impact factor: 5.081

8.  [Diabetic neuropathy].

Authors:  Monika Lechleitner; Heidemarie Abrahamian; Mario Francesconi
Journal:  Wien Klin Wochenschr       Date:  2012-12       Impact factor: 1.704

9.  Sensory loss, pains, motor deficit and axonal regeneration in length-dependent diabetic polyneuropathy.

Authors:  G Said; D Baudoin; K Toyooka
Journal:  J Neurol       Date:  2008-09-25       Impact factor: 4.849

10.  Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients.

Authors:  Dan Ziegler; Lusine Movsesyan; Boris Mankovsky; Irina Gurieva; Zhangentkhan Abylaiuly; Igor Strokov
Journal:  Diabetes Care       Date:  2009-05-26       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.